High-dose-rate brachytherapy using inverse planning optimization with tandem and ovoid applicators for locally advanced cervical cancer: a simulation study

The purpose of this study was to evaluate the dosimetric advantage of inverse planning optimization (IPO) in locally advanced cervical cancer using high-dose-rate (HDR) brachytherapy (BT). IPO was compared with point A plan and geometric optimization (GO). The three planning methods were evaluated using doses to the virtual organ-at-risk (OAR) and D90 (the minimum dose covering of 90% of the volume) to the virtual high-risk clinical target volume (HR-CTV) based on quantitative analysis. HR-CTV structures measuring 38.5 cm³ and 59.5 cm³ were created based on the outcomes of a European Group cohort study. The HR-CTVs were located either at the center of the cervix (cervical center model) or shifted toward the left (extensive disease model). The distances from the HR-CTVs to the rectum were set at 0 mm, 3 mm, 5 mm, 8 mm, 10 mm, and 15 mm. We analyzed 336 conditions in this study. All doses were evaluated by conversion to doses in 2-Gy fractions of conventional radiotherapy. The D90 of the HR-CTV using GO and IPO could achieve the desired dose in all conditions, providing better results than that of point A plan. IPO makes it possible to deliver a sufficient dose for the D90 of the HR-CTV while reducing OAR doses with smaller HR-CTV values (< 38.5 cm³) in HDR BT. However, taking into consideration the whole treatment planning time, IPO should be used only when the HR-CTV-to-rectum distance is ≤ 5 mm, and the use of GO cannot spare OARs.